AzaC increase FOXP3⁺ Tregs that may inhibit the proliferation of allogeneic Tconv in vivo. In vivo AzaC treatment (blue) attenuates the proliferation of allogeneic Tconv compared with the PBS control (red, left panel; peripheral blood on day 19 after SCT, gated on CD45.1⁺ donor T cells). This inhibited proliferation of Tconv is likely to be mediated by FOXP3⁺ Tregs induced by AzaC (middle and right; splenocytes on day 19 after SCT, gated on CD45.1⁺ donor T cells). One representative from each group with identical results is shown. AzaC (n = 4), PBS (n = 2).